The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

Through near-complete TTR stabilization, Attruby has been shown to preserve the native function of TTR as a transport protein ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...

BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

Briefly, transthyretin (TTR, also known as prealbumin) is a “transporter” protein manufactured by the liver. TTR carries ...

Heersink School of Medicine have uncovered significant findings regarding the impact of transthyretin, or TTR, protein levels on heart disease risk. The study, recently published in Nature ...

Ribbon depiction of the four subunits that comprise the TTR protein tetramer showing the T4 binding sites along the 2-fold axis and the peripherally bound ligands. This image relates to a paper ...

In hATTR amyloidosis, transthyretin (TTR) protein misfolds and accumulates as amyloid deposits throughout the body. Tegsedi targets the disease at its source by reducing the production of TTR protein.

The primary interest is the treatment’s ability to maintain a significant knockdown of TTR protein, which is anticipated to positively impact cardiovascular outcomes in future trials.